United States v. Holder

135 F.4th 887
Court of Appeals for the Tenth Circuit·Decided April 22, 2025·No. 23-1021·Published

Opinion

FILED

United States Court of Appeals PUBLISH Tenth Circuit

UNITED STATES COURT OF APPEALS April 22, 2025

Christopher M. Wolpert

FOR THE TENTH CIRCUIT Clerk of Court

UNITED STATES OF AMERICA, Plaintiff - Appellee, v. No. 23-1021 BRUCE HOLDER,

Defendant - Appellant.

Appeal from the United States District Court for the District of Colorado (D.C. No. 1:18-CR-381-CMA-GPG-1)

Ann Marie Taliaferro, Brown Bradshaw & Moffat, Salt Lake City, Utah (Benjamin Miller, Salt Lake City, Utah, with her on the briefs) for Defendant-Appellant.

Kyle Brenton, Assistant United States Attorney (Matthew T. Kirsch, Acting United States Attorney, with him on the brief) United States Attorney’s Office, Denver, Colorado, for Plaintiff-Appellee.

Before TYMKOVICH, BALDOCK, and EID, Circuit Judges.

TYMKOVICH, Circuit Judge.

Bruce Holder ran a fentanyl distribution ring that distributed thousands of pills in western Colorado. He was tried and convicted of four federal drug crimes, including two predicated on the death and serious injury of buyers of his product.

Holder alleges that his trial was unconstitutional because the district court’s COVID-19 protocols violated his public trial right. He also contends Colorado’s jury pool unreasonably underrepresents members of certain racial groups. Finally, he argues that several counts were constructively amended at trial, and the evidence could not support the jury’s finding that his fentanyl distribution resulted in a victim’s death.

We AFFIRM. The district court’s restrictions were no more restrictive than necessary to protect public health against the perceived harms from COVID-19. Nor did an unreasonable racial disparity exist in the members of the jury pool. The indictment was not constructively amended as no essential elements were altered. Finally, the jury reasonably found that Holder’s fentanyl distribution resulted in a victim’s death.

I. Background

A. The Underlying Facts 1. The Conspiracy

Holder was accused of managing a network of friends and family to distribute fentanyl. He would instruct his friends and family to drive from Grand Junction, Colorado to Sonora, Mexico. While they vacationed in Puerto Peñasco, their cars would be stocked with fentanyl. Each time, more than 2,000 pills would be stashed in hidden compartments in the cars. By the summer of 2017, Holder’s wife, Marie Matos, was making the trip to Mexico every two weeks, bringing back more than 50,000 pills.

The pills they brought back were counterfeits that looked like regular oxycodone. They were small, circular, blue, and were stamped with a capital M inside a box on one side and the number thirty on the other. They were made to appear exactly like oxycodone manufactured by Mallinckrodt Pharmaceuticals—the “box M” is Mallinckrodt’s trademark. Holder knew that these were counterfeit pills that contained fentanyl.

Holder’s friends and family would distribute the pills. Holder’s circle included his wife, son, daughter, stepdaughter, and several close friends. All of whom testified that Holder was the ringleader of the conspiracy controlling the supply and prices.

2. The Overdoses

Zack Green both used and sold Holder’s pills. Green bought pills either from Holder directly or through Holder’s distributor, Christopher Huggett. Holder and Huggett were Green’s only source of pills, and Green knew of no other source for blue fentanyl pills in the area.

Green often sold the pills he bought to his coworker, Jon Ellington. On December 26, 2017, Ellington gave Green cash for ten pills. Green then bought twelve pills from Huggett who bought them from Holder. He kept two for himself and delivered the rest to Ellington. Two days later, Green smoked one of those blue pills in his car at work. He took two hits, put the car in drive, and passed out. The assistant manager found Green unconscious when his vehicle hit the building. She

pulled Green from the car and called 911. The paramedics administered Narcan and took Green to the hospital. Green was discharged a few hours later.

On the same day as Green’s episode, Ellington’s housemate found him overdosed in his room. Ellington had not shown up for work for two days, and, after receiving a call from Ellington’s employer, his housemate found him slumped over in a chair in his room. Paramedics administered Narcan but could not revive him.

Ellington had a syringe in his lap and a tourniquet on the floor between his legs. On his dresser, his housemates found a spoon and cotton ball with blue residue on them. They also found several pill bottles in that dresser. One bottle contained a pill that was the same color blue as the residue. The rough markings the housemates described were later identified as the “box M” consistent with Holder’s fentanyl pills. Other substances were also found in Ellington’s room. Law enforcement found one irregular pill identified as MDMA, a stimulant and psychedelic drug also known as ecstasy, and a tan substance identified as DMT, a powerful psychedelic drug.

The toxicology reports pointed to fentanyl as the cause of death. Ellington’s blood tests found a fentanyl concentration of 18 nanograms per milliliter—between six and nine times higher than expected from a typical prescription fentanyl patch. Two coroners concluded that this concentration was the but-for cause of Ellington’s death. Although the defense’s expert forensic pathologist recognized fentanyl intoxication as “a correct cause of death,” she refused to conclude it with certainty because testing was limited. R., Vol. VIII at 1273. She pointed out that the basic toxicology test did not examine Ellington’s urine and did not test for DMT even

though the substance was found in his room. The only substance other than fentanyl the basic test detected was THC.

B. Holder’s Prosecution 1. The Indictment

The second superseding indictment charged six defendants with a total of sixteen counts. Holder went to trial on four counts: (1) conspiracy to distribute 400 grams or more of counterfeit fentanyl, (2) distribution of fentanyl resulting in the death of Ellington, (3) distribution of fentanyl resulting in serious bodily injury to Green, and (4) distribution of a counterfeit controlled substance. See 21 U.S.C. § 841(a)–(b).

2. The Jury Venire

The District of Colorado’s Jury Plan provides that the Master Jury Wheel will come from a source list made up of the Colorado General Election Voter Registration List supplemented by the list of licensed drivers and state-issued adult identification cards. From this “master wheel” jurors are randomly selected for a given grand or petit jury.

When the court imports names from the voter registration list, it only imports voters that are marked “active.” A voter is marked “inactive” if mail sent to that voter by the county clerk is returned. When the jury wheel for this trial was last refilled, inactive voters made up 13.94% of all registered voters. R., Vol. II at 961.

3. The Trial

Holder was indicted by a Grand Jury in Grand Junction, Colorado, and was set to be tried there. But Holder’s trial began on March 13, 2020, the same day President Trump declared a national emergency due to COVID-19. Not enough potential jurors showed up to empanel a jury that day. The court and parties worked for over a year to set and reset trial dates while navigating changing pandemic protocols.

Free access — add to your briefcase to read the full text and ask questions with AI

United States v. Holder, 135 F.4th 887 (10th Cir. 2025).

135 F.4th 887 (United States v. Holder) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

United States v. Smith
Tenth Circuit, 2026